Compare Amphastar Pharmaceuticals Inc (AMPH) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.48 (market cap $826.08M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $119.43. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | QQQE | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $122.72 |
52-Week Low | $16.87 | $96.06 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
QQQE trades at $120.61, up slightly by 0.03% today, with a bullish technical signal driven by strong moving average alignment. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap-weighted peers. Recent news highlights its appeal amid SpaceX's imminent Nasdaq-100 inclusion and as a defensive play in uncertain markets.
The outlook is positive due to structural diversification benefits and potential inflows from index changes. Risks include market volatility and interest rate sensitivity. Analysts favor QQQE for balanced Nasdaq exposure, but its performance remains tied to broader tech sector health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
